FDA Says "No" to Office Use. FDA's letter to Representatives Griffith, Green & DeGette today clearly stated it is interpreting 503A to only permit the compounding of prescriptions for individual patients. This is in direct contradiction to Congressional intent as included in several "Statements of the Record" from Senators and Congressmen that nothing in the Drug Quality & Security Act was intended to interfere with state authority over the practice of pharmacy. Click http://bit.ly/1ph71pk to read FDA's letter.
Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment